Current Report Filing (8-k)
August 12 2019 - 3:07PM
Edgar (US Regulatory)
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of the
Securities Exchange Act of 1934
|
|
Date of Report:
August 12, 2019
(Date of earliest event
reported)
|
|
ImmuCell Corporation
(Exact name of registrant
as specified in its charter)
|
|
DE
(State or other jurisdiction
of incorporation)
|
001-12934
(Commission File Number)
|
01-0382980
(IRS Employer Identification Number)
|
|
56 Evergreen Drive
Portland, Maine
(Address of principal executive
offices)
|
|
04103
(Zip Code)
|
|
207-878-2770
(Registrant's telephone number,
including area code)
|
|
|
|
Not Applicable
(Former Name or Former Address,
if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act: None
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
o
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 2.02. Results of Operations and Financial
Condition
On August 12, 2019 ImmuCell
Corporation (the "Company") issued a press release announcing unaudited financial results for the three-month and six-month
periods ended June 30, 2019. The full text of the press release issued in connection with the announcement is attached as Exhibit
99.1 to this Current Report on Form 8-K.
The information shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise
subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Date: August 12, 2019
|
IMMUCELL CORPORATION
|
|
|
|
|
|
|
By:
|
/s/
Michael F. Brigham
|
|
|
|
Michael F. Brigham
|
|
|
|
President, Chief Executive Officer and Principal Financial Officer
|
|
|
|
|
Exhibit Index
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2023 to Apr 2024
